Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 15/20 | 0.41 |
| ▸ | PTGER3 | P43115 | 8/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.36 |
| ▸ | PER2 | O15055 | 1/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893157 | 0.81 | PTGER2 (0.42) | PTGER2PTGER3MAP4K1PTGER4PTGDR | |
| SCHEMBL9893023 | 0.81 | PER2 (0.46) | PTGER2PTGER3MAP4K1PTGDRPER2 | |
| SCHEMBL9892975 | 0.81 | PTGER2 (0.44) | PTGER2PTGER3PTGER4PTGDRMEN1 | |
| SCHEMBL9892983 | 0.80 | PTGER2 (0.46) | PTGER2PTGER3MAP4K1PTGER4PTGDR | |
| SCHEMBL16480413 | 0.80 | CCNA2 (0.41) | PTGER2PTGER3MAP4K1PER2ALDH1A1 | |
| SCHEMBL9892982 | 0.78 | PTGS2 (0.44) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9892985 | 0.78 | PTGER2 (0.48) | PTGER2PTGER3MAP4K1PTGDRPER2 | |
| SCHEMBL9892973 | 0.78 | ELANE (0.43) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9893017 | 0.77 | KMT2A (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL9891743 | 0.76 | PTGER2 (0.36) | PTGER2PTGER3PTGDRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PTGER2 186/4885PTGER3 200/4885MAP4K1 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.